InspireMD Reports 39.4% Revenue Growth in Q3 2025, Faces Increased Losses

InspireMD, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a significant increase in revenue driven by the commercial launch of its CGuard Prime carotid stent system in the United States. The company generated revenues of $2.5 million for the third quarter, a 39.4% increase from $1.8 million in the same period last year. For the nine months, revenues rose 15.2% to $5.8 million compared to $5.1 million in 2024. Despite this growth, InspireMD reported a net loss of $12.7 million for the third quarter, up from a loss of $7.9 million in the prior year, and a net loss of $37 million for the nine months, compared to $22.8 million in 2024.

The increase in revenue was primarily attributed to the successful launch of the CGuard Prime product following FDA approval in June 2025, which contributed $490,000 to revenue in North America. Additionally, international sales of the CGuard product through distributors also saw growth, adding $223,000. Gross profit for the third quarter increased by 108.7% to $864,000, with gross margins improving to 34.2% from 22.9% year-over-year. However, operating expenses surged, with research and development costs decreasing slightly to $3.6 million, while selling and marketing expenses skyrocketed by 198.4% to $4.4 million, reflecting increased staffing and promotional efforts for the U.S. launch.

In terms of operational developments, InspireMD's total assets increased to $78.5 million as of September 30, 2025, up from $46.8 million at the end of 2024. Cash and cash equivalents also saw a substantial rise to $63.4 million, compared to $18.9 million at the end of the previous year. The company’s equity increased to $64.1 million, reflecting a successful private placement that raised approximately $40.1 million in August 2025. The company’s employee headcount has also grown, driven by the expansion of its U.S. operations.

Looking ahead, InspireMD faces challenges related to its ongoing losses and the need for additional capital to sustain operations. The company has expressed substantial doubt about its ability to continue as a going concern without further financing. Management plans to continue the commercialization of its products and is exploring options for raising capital through equity sales, debt, or strategic partnerships. The company is also focused on expanding its market presence and product adoption, particularly in the U.S. market, where it aims to establish the CGuard Prime as a viable alternative to traditional vascular surgery. However, the success of these initiatives remains uncertain, particularly in light of the competitive landscape and the need for effective marketing and distribution strategies.